CJC-1295 (no DAC)
A growth-hormone-releasing hormone (GHRH) analog — the “no-DAC” form for short, natural GH pulses.
CJC-1295 without DAC (also called Mod GRF 1-29) is a GHRH analog that stimulates growth-hormone release in short, natural pulses. The “no-DAC” form has a shorter half-life, which many clinicians prefer for more physiologic dosing.
Prescription required. Final clinical decisions rest with the prescribing physician.
What is CJC-1295 (no DAC)?
CJC-1295 is a modified GHRH analog that signals the pituitary to release growth hormone. The no-DAC version (Mod GRF 1-29) acts over a shorter window, producing GH pulses closer to the body’s natural rhythm than the longer-acting DAC form.
It’s most often combined with Ipamorelin so the two stimulate GH through complementary pathways. CJC-1295 is accessed through licensed compounding pharmacies under physician prescription; it is not an FDA-approved finished product.
Potential benefits
GHRH-driven GH release
Stimulates the pituitary to release growth hormone in natural pulses.
Short, physiologic action
The no-DAC form has a shorter half-life for more natural dosing.
Pairs with Ipamorelin
Complementary pathways amplify GH release when combined.
Recovery & body composition
Used in protocols targeting recovery and lean mass.
How it works
How it’s taken
A small subcutaneous injection, frequently combined with Ipamorelin; dose and timing set by the physician.
Typical protocol
Run in cycles with periodic reassessment; often dosed at night and/or post-exercise per protocol.
How ordering works
Complete the intake
Share your goals, health history, and current medications — about 5 minutes.
Physician evaluation
An independent, board-certified physician reviews your intake and, if appropriate, prescribes CJC-1295 (no DAC) with a dosing protocol.
Compounded & shipped
The prescription is filled by a licensed compounding pharmacy and shipped to your door with instructions.
What to know before CJC-1295 (no DAC)
CJC-1295 (no DAC) is a bioactive compound. The physician you’re connected with will review the relevant risks and contraindications for your situation before prescribing.
- •Injection-site reactions are the most common side effect.
- •May cause mild water retention, flushing, or head-rush after dosing.
- •Active cancer or recent malignancy is a contraindication for GH-stimulating peptides.
- •Pregnancy and breastfeeding are contraindications for most peptides.
- •Source matters: gray-market “research only” peptides skip physician oversight and quality testing. FirstCall connects you with a licensed physician and a compounding pharmacy that follows USP standards.
CJC-1295 (no DAC) FAQ
What is CJC-1295 used for?
CJC-1295 stimulates the body’s growth-hormone release for recovery and body composition. It’s prescribed off-label under physician supervision.
What does “no DAC” mean?
DAC (Drug Affinity Complex) extends a peptide’s half-life. The no-DAC form acts over a shorter window, giving GH pulses closer to the body’s natural pattern.
Is CJC-1295 FDA-approved?
No. It is prepared by licensed compounding pharmacies and prescribed off-label; it is not an FDA-approved finished drug product.
How is it taken?
A small subcutaneous injection, often paired with Ipamorelin; the physician sets your dose and schedule.
How much does it cost?
CJC-1295 starts from $149/month. Final pricing is confirmed by the compounding pharmacy after your physician evaluation. The initial evaluation is free.
Ready to start CJC-1295 (no DAC)?
Complete a short medical intake — a supervising physician reviews it and, if appropriate, writes your prescription, and a licensed pharmacy ships to your door.
Pricing & regulatory note: The $149/mo price is an indicative starting point confirmed by the compounding pharmacy after physician evaluation. CJC-1295 (no DAC) is not an FDA-approved finished drug product; it is prepared by licensed compounding pharmacies and prescribed off-label. FDA guidance on peptide compounding continues to evolve and availability can change. A prescription is required.